Table 2 Change from baseline to last follow-up in asthma patients with or without previous mepolizumab treatment
all patients(n = 24) | previous mepolizumab treatment (−) (n = 13) | previous mepolizumab treatment (+) (n = 11) | P value between two groups at baseline | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
baseline | last follow up | P value | baseline | last follow up | P value | baseline | last follow up | P value | P value | |
peripheral blood eosinophil counts (/μl) | 292 (312) | 0 (0) | < 0.0001† | 458 (338) | 0 (0) | 0.0015† | 95 (88) | 0 (0) | 0.0033† | 0.0005† |
peripheral blood basophil counts (/μl) | 35 (27) | 7 (9) | < 0.0001† | 35 (26) | 6 (5) | 0.0015† | 35 (30) | 8 (13) | 0.0033† | 0.95 |
serum IgE (IU/ml) | 232(198) | 325 (674) | 0.70 | 263 (186) | 232 (225) | 0.48 | 196 (213) | 436 (980) | 0.88 | 0.27 |
FeNO (ppb) | 59 (39) | 67 (53) | 0.41 | 64 (43) | 71 (58) | 0.70 | 52 (32) | 61 (47) | 0.40 | 0.53 |
%FVC (%) | 94.9 (14.9) | 97.9 (14.3) | 0.11 | 96.1 (16.6) | 101.5 (14.2) | 0.028 | 93.4 (13.2) | 93.7 (13.9) | 0.76 | 0.52 |
%FEV1 (%) | 78.4 (21.9) | 81.9 (21.2) | 0.017 | 79.8 (26.2) | 84.6 (24.1) | 0.006 | 76.8 (16.6) | 78.8 (17.8) | 0.53 | 0.98 |
FEV1/FVC (%) | 67.2 (10.8) | 68.4 (12.3) | 0.29 | 67.1 (12.1) | 67.9 (12.5) | 0.35 | 67.2 (9.7) | 69.0 (12.7) | 0.53 | 0.75 |
FEV1 (ml) | 1978 (596) | 2057 (606) | 0.07 | 1936 (783) | 2053 (778) | 0.017 | 2026 (275) | 2061 (346) | 0.96 | 0.04 |
%PEF (%) | 83.9 (24.8) | 84.1 (24.4) | 0.72 | 86.6 (29.9) | 88.0 (27.5) | 0.70 | 80.6 (17.9) | 79.0 (19.8) | 0.22 | 0.88 |
ACT (pts) | 19.2 (4.8) | 20.3 (4.9) | 0.08 | 17.8 (5.9) | 20.2 (5.5) | 0.08 | 20.9 (1.8) | 20.3 (4.3) | 0.51 | 0.51 |
number of annual exacerbations | 2.8 (3.4) | 1.8 (3.2) | 0.28 | 3.6 (4.0) | 1.7 (3.5) | 0.10 | 1.8 (2.3) | 2.0 (2.8) | 0.67 | 0.31 |
prednisolone equivalent dose (mg/day) | 5.6 (4.2) | 3.3 (2.5) | 0.11 | 6.1 (4.7) | 3.0 (2.6) | 0.11 | 4.3 (2.5) | 4.3 (2.5) | – | 0.74 |